Schedule Update - effective 1 April 2010 (text extract)

This is the text extract for Schedule Update - effective 1 April 2010, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 April 2010 Cumulative for January, February, March and April 2010 Section H for April 2010

Contents

Summary of PHARMAC decisions effective 1 April 2010 ............................... 3 Diclofenac sodium SR 75 mg long-acting tablets – stock management ........ 4 New treatment for Pulmonary Arterial Hypertension .................................... 4 New brand of topiramate available ............................................................... 5 Travoprost – reference pricing ....................................................................... 5 Alendronate for osteoporosis – amended Special Authority criteria .............. 5 Prednisolone acetate eye drops now fully subsidised .................................... 6 Imiquimod – amended Special Authority criteria........................................... 6 Nilstat tablets now registered ....................................................................... 6 Acebutolol – discontinuation ........................................................................ 6 Withdrawal of dextropropoxyphene-containing medicines ........................... 7 Prefixes on Special Authority numbers .......................................................... 8 Morphine sulphate 200 mg long-acting capsules - discontinuation .............. 9 Mitomycin-C injection 10 mg ........................................................................ 9 Tender News ................................................................................................ 10 Looking Forward ......................................................................................... 10 Sole Subsidised Supply products cumulative to April 2010 ......................... 11 New Listings ................................................................................................ 20 Changes to Restrictions ............................................................................... 24 Changes to Subsidy and Manufacturer’s Price............................................. 34 Changes to General Rules............................................................................ 40 Changes to Sole Subsidised Supply ............................................................. 40 Changes to Section E Part I ......................................................................... 40 Delisted Items ............................................................................................. 41 Items to be Delisted .................................................................................... 45 Section H changes to Part II ........................................................................ 49 Section H changes to Part IV ....................................................................... 50 Index ........................................................................................................... 51

Summary of PharmaC decisions

effeCtIve 1 aPrIL 2010 New listings (page 20) • Bisacodyl (Dulcolax) suppos 10 mg – Only on a prescription • Docusate sodium tab 50 mg (Laxofast 50) and 120 mg (Laxofast 120) – Only on a prescription • Ambrisentan (Volibris) tab 5 mg and 10 mg – Special Authority – Hospital pharmacy [HP1] • Hydrocortisone (Pharmacy Health) crm 1% - Only on a prescription • Danazol (Azol) cap 200 mg – Retail pharmacy – Specialist • Topiramate (Arrow-Topiramate) tab 25 mg, 50 mg, 100 mg and 200 mg Changes to restrictions (pages 24-29) • Imiquimod (Aldara) crm 5% sachet – amended Special Authority criteria • Somatropin (Genotropin) inj cartridge 16 iu (5.3 mg) and 36 iu (12 mg) – amended presentation description • Nystatin (Nilstat) tab 500,000 u – Section 29 status removal • Influenza vaccine (Fluvax, Fluarix, Influvac and Vaxigrip) – amended access criteria • Alendronate for osteoporosis – amended Special Authority criteria • Gabapentin (Nupentin) cap 100 mg, 300 mg and 400 mg – amended Special Authority criteria • Vigabatrin (Sabril) tab 500 mg – amended Special Authority criteria • Travoprost (Travatan) eye drops 0.004% – additional subsidy by endorsement Decreased subsidy (pages 34-35) • Docusate sodium with sennosides (Laxsol) tab 50 mg with total sennosides 8 mg • Hydroxocobalamin (Neo-B12) inj 1 mg per ml, 1 ml • Tranexamic acid (Cyclokapron) tab 500 mg • Somatropin (Genotropin) inj cartridge 16 iu (5.3 mg) and 36 iu (12 mg) • Zidovudine (AZT) (Retrovir) cap 100 mg and oral liq 10 mg per ml • Dihydrocodeine tartrate (DHC Continus) tab long-acting 60 mg • Letrozole (Femara) tab 2.5 mg • Promethazine hydrochloride (Phenergan) oral liq 5 mg per 5 ml • Travoprost (Travatan) eye drops 0.004% Increased subsidy (page 34) • Bisacodyl (Dulcolax) suppos 5 mg • Mitomycin C inj 10 mg (Mitomycin-C) and inj 1 mg for ECP (Baxter) • Chloramphenicol (Chlorsig) eye drops 0.5%

4 Pharmaceutical Schedule - Update News

Diclofenac sodium SR 75 mg long-acting tablets – stock management

Voltaren SR 75 mg long-acting tablets (diclofenac sodium), supplied by Novartis, were listed in the Pharmaceutical Schedule from October 2009 to cover an out-of-stock. The Voltaren SR brand of diclofenac sodium 75 mg long-acting tablets will be delisted from the Pharmaceutical Schedule from 1 June 2010. The Diclax SR brand will remain listed. Monthly dispensing under Close Control rules will continue at this stage on diclofenac sodium long-acting tablets 75

mg and 100 mg. We will notify pharmacy via fax of the end date of Close Control for these products. We would like to thank pharmacies and wholesalers for their patience during this out-of-stock.

New treatment for Pulmonary Arterial Hypertension

From 1 April 2010 a new product will be subsidised for the management of pulmonary arterial hypertension (PAH). Ambrisentan (Volibris) 5 mg and 10 mg tablets will be subsidised via application to the Pulmonary Arterial Hypertension Panel. Application forms will be available on our website. Special Authority approvals for bosentan will be interchangeable with ambrisentan.

Pharmaceutical Schedule - Update News

New brand of topiramate available

An additional brand of topiramate tablets will be subsidised from 1 April 2010. ArrowTopiramate 25 mg, 50 mg, 100 mg and 200 mg strengths will be subsidised.

Travoprost – reference pricing

From 1 April 2010 the subsidy for travoprost (Travatan) eye drops 0.004% will reduce to match that of latanoprost eye drops 50 µg per ml, 2.5.ml (Hysite). This will result in a manufacturer’s surcharge on Travatan eye drops as the price has not been reduced to match the subsidy. Bimatoprost and latanoprost remain fully subsidised. For patients taking travoprost eye drops prior to 1 April 2010 a full subsidy will be available until 30 September 2010 under endorsement criteria. (See page 29 for full details). Pharmacists may annotate prescriptions for patients who were being prescribed travoprost prior to 1 April 2010 in which case the prescription is deemed to be endorsed. The pharmacist must be able to show a clear dispensing history for the patient. Clinical feedback to consultation on this change suggested treatment with travoprost was exclusively initiated by ophthalmologists. The six month transition period is provided to allow patients sufficient time to return to their ophthalmologist for a review of their medication if they wish to switch to a fully subsidised alternative.

Alendronate for osteoporosis – amended Special Authority criteria

The Special Authority criteria applying to alendronate for osteoporosis will be amended from 1 April 2010. The Special Authority for alendronate with or without cholecalciferol (Fosamax and Fosamax Plus) will be amended to clarify that T-Scores must be derived using dual-energy x-ray absorptiometry (DXA). The definition of BMD will also be corrected from bone mass density to bone mineral density.

6 Pharmaceutical Schedule - Update News

Prednisolone acetate eye drops now fully subsidised

Following an agreement with Allergan NZ Ltd the prices for Pred Mild and Pred Forte (prednisolone acetate) eye drops have been reduced to match the current subsidies. This means Pred Mild eye drops 0.12% and Pred Forte eye drops 1% will be fully subsidised and gives prescribers an alternative fully subsidised ocular topical corticosteroid.

Imiquimod – amended Special Authority criteria

The Special Authority criteria for imiquimod cream 5% will be amended from 1 April 2010. There has been some confusion over whether or not a biopsy was required when completing a renewal application for imiquimod. A biopsy is preferred but not a mandatory requirement on renewal applications. Although a biopsy is preferred before imiquimod is used, it is not compulsory. We would however reinforce when imiquimod has failed a biopsy should ideally be considered. The Special Authority criteria has been amended to make this clear. Imiquimod is not funded for actinic keratosis (solar keratosis).

Nilstat tablets now registered

Nilstat (nystatin) 500,000 u tablets have been approved by Medsafe for distribution within New Zealand. The funded brand of nystatin has been supplied under Section 29 of the Medicine Act since early 2007; however, this restriction no longer applies.

Acebutolol – discontinuation

Mylan New Zealand Limited has advised that ACB 200 mg capsules are to be discontinued from 1 April 2010. This brand will be delisted from the Pharmaceutical Schedule from 1 October 2010. PHARMAC is not seeking a replacement for this pharmaceutical.

Pharmaceutical Schedule - Update News

Withdrawal of dextropropoxyphene-containing medicines

In December 2009 the Medicines Adverse Reactions Committee (MARC) of Medsafe reviewed the benefits and risks of dextropropoxyphene containing medicines. The MARC assessed the published literature; adverse reactions reported in New Zealand and internationally; NZ Poisons Centre data; and the results of a Paradex utilisation study conducted in New Zealand in 2007. The MARC also considered reviews conducted by other medicine regulators. In the interests of public safety, the MARC has recommended that Capadex and Paradex be withdrawn from New Zealand. Medsafe supports the MARC's conclusions and is currently implementing their recommendation. In recognition of the significant number of patients currently taking dextropropoxyphene-containing medicines, the withdrawal will not be immediate to allow sufficient time for patients to be transferred to alternative medications. In the interim, Medsafe advises the following: • Do not start any new patients on Paradex or Capadex. • Analgesic requirements of patients currently taking Paradex or Capadex should be reviewed at the earliest opportunity. • In the UK, where this medicine has already been withdrawn, there is evidence to show that the majority of patients were successfully transitioned to full dose paracetamol alone, codeine alone or paracetamol/codeine combination products. • As dextropropoxyphene is an opiate, similar adverse effects may be seen to those observed with other opiates and it may therefore not be appropriate to abruptly stop this medicine for some patients. PHARMAC staff intend to recommend to the PHARMAC Board (or Chief Executive acting under delegated authority) that Paradex and Capadex be delisted from the Pharmaceutical Schedule from the date that registration is revoked. There would be no transition period to allow stock to be sold through. Medsafe will be advising of the date that the consents for Capadex and Paradex will be revoked shortly. It is anticipated that the revocation date will be between 1 August 2010 and the end of this year. For further information from Medsafe on the withdrawal of dextropropoxyphenecontaining medicines please refer to its website http://www.medsafe.govt.nz/hot/ MediaContents.asp.

8 Pharmaceutical Schedule - Update News

Prefixes on Special Authority numbers

PHARMAC has received some queries on what the prefixes on the Special Authority numbers refer to. Below is a summary table that explains the prefixes, which may assist prescribers and pharmacies. The summary table is also published in the Pharmacy Procedures Manual. Please note that the prefixes should be written on the prescription along with the number and expiry date. Prefix CHEM EXCP SA Type Special Authority Community Exceptional Circumstances Description Allows patients to receive funded Special Authority medicines through a Community Pharmacy Allows a patient to access a subsidy sufficient to fully fund the pharmaceutical that is not subsidised on the Pharmaceutical Schedule. Criteria and application details are described in the Pharmaceutical Schedule. Special Foods This prefix indicates that either: a. the doctor has requested a complete diet for their patient, or b. the medicine can only be dispensed by a hospital pharmacy. RISK Risk Number Available where a Pharmacy has made a dispensing in good faith or if the patient has a life threatening condition. This prefix indicates that either: a. the prescriber has requested a supplement diet for their patient, restricted to 500 ml per day or as defined in the Pharmaceutical Schedule, or b. to waive a restriction TEMP Templeton Enables subsidy for patients who were residents at the Templeton Centre at the time of closure. The approval numbers cover all medicines required by the patient. Note: The prefix HOSP or SPEC is only required on a prescription if Special Foods have been prescribed.

HOSP

Special Authority

SPEC

Special Authority

Pharmaceutical Schedule - Update News

Special Foods Prefixes are used to identify whether a Special Authority has been allocated for complete diet or for supplementary purposes. a. A HOSP number for the purposes of a Special Food is an indication that the doctor has requested a complete diet for their patient. b. A SPEC number for the purposes of a Special Food is an indication that the doctor requested a supplement diet for their patient, restricted to 500 ml per day or as defined in the Pharmaceutical Schedule.

Morphine sulphate 200 mg long-acting capsules discontinuation

Multichem NZ Ltd has advised that m-Eslon (morphine sulphate) 200 mg long-acting capsules are to be discontinued upon depletion of the existing stock. Multichem anticipates this to occur by August/ September 2010. It will be delisted from the Pharmaceutical Schedule 6 months following this date. PHARMAC is not seeking a replacement for the 200 mg strength of morphine sulphate capsules. Morphine sulphate 100 mg long-acting capsules and 100 mg long-acting tablets remain fully subsidised.

Mitomycin-C injection 10 mg

The Mitomycin C brand of mitomycin-C injection 10 mg will remain listed. Previously we have notified the discontinuation of this product in New Zealand. It was due to be delisted from 1 June 2010 but this decision has been revoked to enable claiming for this product if sourced from overseas. The subsidy and price for Mitomycin-C 10 mg injection will increase, as will the subsidy and price for the injection 1 mg for ECP (Baxter). Mitomycin-C injection 10 mg remains a Section 29 medicine.

tender News

Sole Subsidised Supply changes – effective 1 May 2010

Chemical Name Amoxycillin Calcitriol Calcitriol Metformin hydrochloride Metformin hydrochloride Permethrin Pizotifen Sumatriptan Sumatriptan Presentation; Pack size Grans for oral liq 250 mg per 5 ml; 100 ml Cap 0.25 µg; 30 tab Cap 0.5 µg; 30 tab Tab immediate-release 500 mg; 500 tab Tab immediate-release 850 mg; 250 tab Lotn 5%; 30 ml OP Tab 500 µg; 100 tab Tab 50 mg; 100 tab Tab 100 mg; 100 tab Sole Subsidised Supply brand (and supplier) Ospamox (Sandoz) Airflow (Airflow) Airflow (Airflow) Apotex (Apotex) Apotex (Apotex) A-Scabies (AFT) Sandomigran (Novartis) Arrow-Sumatriptan (Arrow) Arrow-Sumatriptan (Arrow)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 may 2010 • Gemcitabine hydrochloride inj 200 mg and 1 g (Gemcitabine Ebewe and Gemzar), and inj 1 mg for ECP (Baxter) – amended Special Authority criteria • Lignocaine (Pfizer) gel 2% urethral syringe 10 ml – new listing • Sumatriptan (Arrow-Sumatriptan) tab 50 mg (4-tablet pack) and 100 mg (2-tablet pack) - continued listing from 1 May 2010 (i.e. reversal of previous decision to delist the smaller pack sizes of Arrow-Sumatriptan from 1 May 2010) • Vinorelbine inj 10 mg per ml, 1 mg and 5 ml (Navelbine and Vinorelbine Ebewe), and inj 1 mg for ECP (Baxter) – amended Special Authority criteria Decision for implementation 1 July 2010 • Metoprolol succinate (AFT-Metoprolol CR and Betaloc CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg – subsidy decrease

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Acarbose Acetazolamide Allopurinol Alprazolam Amantadine hydrochloride Amlodipine Amoxycillin

Presentation

Tab 50 mg & 100 mg Tab 250 mg Tab 100 mg & 300 mg Tab 250 µg, 500 µg & 1 mg Cap 100 mg Tab 5 mg & 10 mg Drops 125 mg per 1.25 ml Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg

Brand Name Expiry Date*

Glucobay Diamox Apo-Allopurinol Arrow-Alprazolam Symmetrel Apo-Amlodipine Ospamox Paediatric Drops Ibiamox Apo-Amoxi Curam Curam Synermox AFT Ethics Aspirin Ethics Aspirin EC Pacific Atenolol AstraZeneca Arrow-Azithromycin Pacifen Sandoz Beta Scalp Fibalip Bicalox Lax-Tabs AFT Marcain Isobaric Marcain Heavy healthE API Miacalcic Calsource Calcium Folinate Ebewe Apo-Captopril 2011 2011 2010 2012 2012 2012 2012 2011 2012 2011 2011 2010 2011 2010 2012 2011 2011 2011 2010 2012 2011 2011 2010 2011 2011 2011 2010 2012

Amoxycillin clavulanate

Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab amoxycillin 500 mg with potassium clavulanate 125 mg Crm 500 g Tab dispersible 300 mg Tab 100 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Tab 500 mg Tab 10 mg Inj 1 mega u Scalp app 0.1% Tab 200 mg Tab 50 mg Tab 5 mg Eye drops 0.2% Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Crm, aqueous, BP Lotn, BP Inj 100 iu per ml, 1 ml Tab eff 1 g Inj 50 mg Tab 12.5 mg, 25 mg & 50 mg

Aqueous cream Aspirin Atenolol Atropine sulphate Azithromycin Baclofen Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Bezafibrate Bicalutamide Bisacodyl Brimonidine tartrate Bupivicaine hydrochloride Calamine Calcitonin Calcium Calcium folinate Captopril

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Cefaclor monohydrate Cefazolin sodium Cefuroxime sodium Cephalexin monohydrate Cetomacrogol Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate Ciclopiroxolamine Ciprofloxacin Citalopram Clarithromycin Clobetasol propionate

Presentation

Cap 250 mg Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 750 mg & 1.5 g Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Crm BP Tab 10 mg Oral liq 1 mg per ml Eye oint 1% Soln 4% Nail soln 8% Tab 250 mg, 500 mg & 750 mg Tab 20 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Crm 0.05% Oint 0.05% Scalp app 0.05% Tab 500 µg & 2 mg TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg Crm 1% Vaginal crm 1% with applicator(s) Vaginal crm 2% with applicators(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs

Brand Name Expiry Date*

Ranbaxy-Cefaclor Ranbaxy-Cefaclor Hospira Zinacef Cefalexin Sandoz Cefalexin Sandoz PSM Zetop Cetirizine-AFT Chlorsig Orion Batrafen Rex Medical Arrow-Citalopram Klamycin Klacid Dermol Dermol Dermol Paxam Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Dixarit Catapres Clomazol Clomazol Clomazol PSM Colgout Colestid Colistin-Link Enerlyte Nausicalm Cycloblastin Siterone Ginet 84 2010 2011 2011 2012 2010 2011 2012 2011 2012 2011 2011 2010 2012

Clonazepam Clonidine

2011 2012

Clonidine hydrochloride

2012

Clotrimazole

2011 2010 2010 2010 2010 2010 2010 2012 2010 2012 2011

Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Cyproterone acetate with ethinyloestradiol

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Desferrioxamine mesylate Desmopressin Dexamphetamine sulphate Dextrose Dextrose with electrolytes

Presentation

Inj 500 mg Nasal spray 10 µg per dose Tab 5 mg Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Mayne Desmopressin-PH&T PSM Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Diclohexal Voltaren Ophtha Voltaren Voltaren Dilzem Cardizem CD Pytazen SR Apo-Doxazosin AFT Clexane Comtan E-Mycin E-Mycin E-Mycin NZ Medical and Scientific Brevinor 21 Brevinor 1/21 Brevinor 1/28 Arrow-Etidronate Felo 5 ER Felo 10 ER Ferodan Fintral AFT AFT Flucloxin Pacific 2012 2012 2010 2011 2012 2011 2011 2010 2011 2010 2011 2010

Diclofenac sodium

Tab EC 25 mg & 50 mg Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Tab 2 mg & 4 mg Oint BP Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 10 µg Tab 35 μg with norethisterone 500 µg Tab 35 μg with norethisterone 1 mg Tab 35 μg with norethisterone 1 mg and 7 inert tab Tab 200 mg Tab long-acting 5 mg Tab long-acting 10 mg Oral liq 150 mg per 5 ml Tab 5 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg

2012 2011

Diltiazem hydrochloride

2011

Dipyridamole Doxazosin mesylate Emulsifying ointment Enoxaparin sodium (low molecular weight heparin) Entacapone Erythromycin ethyl succinate

2011 2010 2011 2012 2012 2012 2011 2012 2010

Ethinyloestradiol Ethinyloestradiol with norethisterone

Etidronate disodium Felodipine Ferrous sulphate Finasteride Flucloxacillin sodium

Fluconazole

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Fludarabine phosphate Fluocortolone caproate with fluocortolone pivalate and cinchocaine

Presentation

Inj 50 mg Tab 10 mg Oint 950 μg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 μg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1% Cap 20 mg Tab disp 20 mg, scored Metered aqueous nasal spray, 50 µg per dose Tab 40 mg Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg & 10 mg

Brand Name Expiry Date*

Fludara Fludara Oral Ultraproct Ultraproct 2011 2010

Fluoromethalone Fluoxetine hydrochloride Fluticasone propionate Furosemide Fusidic acid Gabapentin Gentamicin sulphate Gliclazide Glipizide Glyceryl trinitrate

FML Fluox Fluox Flixonase Hayfever & Allergy Diurin 40 Foban Foban Nupentin Pfizer Apo-Gliclazide Minidiab Lycinate Nitrolingual Pumpspray Nitroderm TTS Serenace Serenace Douglas ABM PSM Colifoam Locoid DP Lotn HC Plaquenil Methopt Buscopan Gastrosoothe Ethics Ibuprofen Fenpaed

2012 2010 31/1/13 2012 2010 31/7/12 2012 2011 2011 2011

Haloperidol Hydrocortisone

Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Tab 5 mg & 20 mg Powder Crm 1% Rectal foam 10%, CFC-free (14 applications) Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Tab 200 mg Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Tab 200 mg Oral liq 100 mg per 5 ml

2010 2012 2011 2012 2010 2011 2012 2011 2011 2012 2010

Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone with wool fat and mineral oil Hydroxychloroquine sulphate Hypromellose Hysocine N-butylbromide Ibuprofen

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Ipratropium bromide

Presentation

Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Inj 50 mg per ml, 2 ml Cap 10 mg & 20 mg Cap 100 mg Shampoo 2% Oral liq 10 g per 15 ml Eye drops 50 µg per ml Eye drops 0.25% & 0.5% Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Ferrum H Oratane Sporanox Sebizole Duphalac Hysite Betagan Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Derbac M A-Lices Foremount Child’s Silicone Mask De-Worm Colofac Provera Pentasa Biodone Biodone Forte Biodone Extra Forte Methatabs Methoblastin Methotrexate Ebewe Methotrexate Ebewe Prodopa Medrol Depo-Medrol 2012 2010 2010 2010

Iron polymaltose Isotretinoin Itraconazole Ketoconazole Lactulose Latanoprost Levobunolol Lignocaine hydrochloride

2011 2012 2010 2011 2010 2012 2010 2010

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Malathion Mask for Spacer Device Mebendazole Mebeverine hydrochloride Medroxyprogesterone acetate Mesalazine Methadone hydrochloride

Liq 0.5% Shampoo 1% Device Tab 100 mg Tab 135 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 5 mg Tab 2.5 mg & 10 mg Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 125 mg, 250 mg & 500 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml

2010 2011 30/9/11 2011 2011 2010 2012 2012 2010 2012 2011 2011 2012 2011

Methotrexate

Methyldopa Methylprednisolone Methylprednisolone acetate

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate

Presentation

Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Inj 5 mg per ml, 2 ml Crm 2% Crm 0.1% Oint 0.1% Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab immediate release 10 mg & 20 mg Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Tab 40 mg & 80 mg Tab 50 mg Tab 250 mg Tab 500 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 200 mg

Brand Name Expiry Date*

Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Multichem m-Mometasone m-Mometasone RA-Morph RA-Morph RA-Morph RA-Morph Sevredol Mayne Mayne Apo-Nadolol ReVia Noflam 250 Noflam 500 Sonaflam AstraZeneca Viramune Suspension Viramune Habitrol Habitrol Habitrol Habitrol Noriday 28 Primolut N Norpress Nilstat Nilstat Nilstat Dr Reddy’s Omeprazole Dr Reddy’s Omeprazole Zofran Zofran Zydis 2011 2012

Metoclopramide hydrochloride Miconazole nitrate Mometasone furoate Morphine hydrochloride

2011 2011 2012 2012

Morphine sulphate

2012 2011 2010 2010 2012 2010 2010 2012

Nadolol Naltrexone hydrochloride Naproxen Naproxen sodium Neostigmine Nevirapine

Nicotine

Patch 7 mg, 14 mg & 21 mg Lozenge 1 mg & 2 mg Gum 2 mg & 4 mg (Fruit) Gum 2 mg & 4 mg (Mint) Tab 350 µg Tab 5 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml, 24 ml OP Cap 500,000 u Tab 500,000 u Cap 10 mg, 20 mg & 40 mg Inj 40 mg

2010

Norethisterone Nortriptyline hydrochloride Nystatin

2012 2011 2011 2011 2010 2011

Omeprazole

Ondansetron

Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg

2010

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Oxybutynin Oxycodone hydrochloride Oxytocin

Presentation

Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml & 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Inj 40 mg Tab 20 mg & 40 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Eye oint with soft white paraffin Tab 20 mg Low range and Normal range Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 μg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 μg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 μg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 μg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Tab 0.25 mg & 1 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg & 500 mg Eye drops 0.12% Tab 15 mg, 30 mg & 45 mg Oral drops 10% Eye drops 1.4% Eye drops 3% Tab long-acting 600 mg Tab 1 mg, 2 mg & 5 mg Tab 1 mg, 2.5 mg, 5 mg & 20 mg

Brand Name Expiry Date*

Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Pantocid IV Dr Reddy’s Pantoprazole Pharmacare Paracare Junior Paracare Double Strength Lacri-Lube Loxamine Breath-Alert Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax AFT AFT Cilicaine VK Prefrin Pizaccord Coloxyl Vistil Vistil Forte Span-K Apo-Prazo Apo-Prednisone 2010 2010 2012

Pamidronate disodium

2011

Pantoprazole

2010

Paracetamol

2011

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak Flow Meter Pegylated interferon alpha-2A

2010 2010 30/9/11 31/12/12

Pergolide Phenoxymethylpenicillin (Penicillin V) Phenylephrine hydrochloride Pioglitazone Poloxamer Polyvinyl alcohol Potassium chloride Prazosin hydrochloride Prednisone

2011 2010

2010 2012 2011 2011 2012 2010 2011

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Prednisone sodium phosphate Procaine penicillin Promethazine Quinapril Quinapril with hydroclorothiazide

Presentation

Oral liq 5 mg per ml Inj 1.5 mega u Tab 10 mg & 25 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydroclorothiazide 12.5 mg Tab 20 mg with hydroclorothiazide 12.5 mg Tab 300 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg and 5 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Grans eff 4 g sachets Nasal spray, 4% Tab 80 mg & 160 mg 230 ml Liq Soln 2.3% Tab 10 mg Tab 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 µg Inj 1 mg per ml, 1 ml Tab 10 mg Eye drops 0.25% & 0.5%

Brand Name Expiry Date*

Redipred Cilicaine Allersoothe Accupril Accuretic 10 Accuretic 20 Q 300 Peptisoothe Mycobutin Ropin ArrowRoxithromycin Asthalin Asthalin Salapin Duolin 2012 2010 2010 2010 2012 2012 2010 2012 2012 2011 2011 2011 2011

Quinine sulphate Ranitidine hydrochloride Rifabutin Ropinirole hydrochloride Roxithromycin Salbutamol

Salbutamol with ipratropium bromide Selegiline hydrochloride Simvastatin

Apo-Selegiline Arrow-Simva 10 mg Arrow-Simva 20 mg Arrow-Simva 40 mg Arrow-Simva 80 mg Ural Rex Mylan Space Chamber Midwest Pinetarsol Normison Apo-Terazosin Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot Apo-Timol Apo-Timop

2012 2011

Sodium citro-tartrate Sodium cromoglycate Sotalol Spacer Device Syrup (pharmaceutical grade) Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terazosin hydrochloride Terbinafine Testosterone cypionate Tetracosactrin Timolol maleate

2010 2012 2012 30/9/11 2010 2011 2011 2010 2011 2011 2011 2012 2011

Sole Subsidised Supply Products – cumulative to April 2010

Generic Name

Triamcinolone acetonide

Presentation

Crm 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP Tab 300 mg Cap 5 mg Cap 300 mg Inj 50 mg per ml, 10 ml Oint BP Cap 220 mg Tab 7.5 mg

Brand Name Expiry Date*

Aristocort Aristocort Kenacort-A40 Oracort TMP Navoban Actigall Pacific PSM Zincaps Apo-Zopiclone 2011

Trimethoprim Tropisetron Ursodeoxycholic acid Vancomycin hydrochloride Zinc and castor oil Zinc sulphate Zopiclone April changes in bold

2011 2012 2011 2011 2011 2011 2011

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 April 2010

34 34 56 BISACODYL – Only on a prescription ❋ Suppos 10 mg .......................................................................... 3.00 DOCUSATE SODIUM – Only on a prescription ❋ Tab 50 mg ............................................................................... 3.95 ❋ Tab 120 mg ............................................................................. 5.49 AMBRISENTAN – Special Authority see SA0967 – Hospital pharmacy [HP1] Tab 5 mg ........................................................................... 4,585.00 Tab 10 mg ......................................................................... 4,585.00 HYDROCORTISONE ❋ Crm 1% – Only on a prescription .............................................. 3.75 DANAZOL – Retail pharmacy-Specialist Cap 200 mg ........................................................................... 97.83 TOPIRAMATE s Tab 25 mg ............................................................................. 11.07 s Tab 50 mg ............................................................................. 18.81 s Tab 100 mg ........................................................................... 31.99 s Tab 200 mg ........................................................................... 55.19 6 100 100 30 30 100 g 100 60 60 60 60 ✔ Dulcolax ✔ Laxofast 50 ✔ Laxofast 120 ✔ Volibris ✔ Volibris ✔ Pharmacy Health ✔ Azol ✔ Arrow-Topiramate ✔ Arrow-Topiramate ✔ Arrow-Topiramate ✔ Arrow-Topiramate

61 81 118

Effective 1 March 2010

37 VITAMINS ❋ Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1002 – Retail pharmacy .................. 23.40 60 ✔ Vitabdeck ➽ SA1002 Special Authority for Subsidy Initial Application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1. Patient has cystic fibrosis with pancreatic insufficiency; or 2. Patient is an infant or child with liver disease or short gut syndrome. CROTAMITON a) Only on a prescription b) Not in combination Crm 10% ................................................................................... 3.79

20 g OP

✔ Itch-Soothe

CHLORHEXIDINE GLUCONATE - Subsidy by endorsement a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly ❋ Handrub 1% with ethanol 70% ................................................... 4.60 500 ml ✔ healthE PREGNANCY TESTS - HCG URINE – Only on a PSO Cassette – Up to 200 test available on a PSO ........................... 22.80 40 test OP ✔ Innovacon hCG One Step Pregnancy Test Device

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 March 2010 (continued)

99 INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available between 1 March and 30 June each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii)diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin. c) people under 65 years of age who are: i) pregnant; or ii) morbidly obese d) children under the age of 5 who are enrolled with an Access Primary Health Organisation The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease, B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj ........................................................................................... 90.00 10 ✔ Influvac MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg ............................................................................ 57.92 30

146

✔ Apo-Megestrol

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 February 2010

31 BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 meter per prescription b) 1) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005 or is prescribed for a pregnant woman with diabetes. 2) Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Meter ........................................................................................ 9.00 1 ✔ On Call Advanced BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood glucose test strips × 50 and lancets × 5 ...................... 19.10 1 OP ✔ On Call Advanced SUMATRIPTAN Tab 50 mg ............................................................................. 38.83 Tab 100 mg ........................................................................... 77.66 RISPERIDONE Tab 0.5 mg .............................................................................. 3.51 Tab 1 mg ................................................................................. 6.00 Tab 2 mg ............................................................................... 11.00 Tab 3 mg ............................................................................... 15.00 Tab 4 mg ............................................................................... 20.00 Oral liq 1 mg per ml ................................................................ 18.35 134 100 100 60 60 60 60 60 30 ml ✔ Arrow-Sumatriptan ✔ Arrow-Sumatriptan ✔ Apo-Risperidone ✔ Apo-Risperidone ✔ Dr Reddy’s Risperidone ✔ Apo-Risperidone ✔ Dr Reddy’s Risperidone ✔ Apo-Risperidone ✔ Dr Reddy’s Risperidone ✔ Apo-Risperidone ✔ Dr Reddy’s Risperidone ✔ Apo-Risperidone

119

125

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see SA0924 – Retail pharmacy Only on a controlled drug form Cap modified-release 10 mg ................................................... 19.50 30 ✔ Ritalin LA DASATINIB – Special Authority see SA0976 Tab 100 mg ...................................................................... 6,214.20 LETROZOLE Tab 2.5 mg ............................................................................ 26.55 PROMETHAZINE HYDROCHLORIDE ❋‡ Oral liq 5 mg per 5 ml ............................................................. 3.10 FLUTICASONE PROPIONATE Metered aqueous nasal spray, 50 µg per dose ......................... 13.34 30 30 100 ml ✔ Sprycel ✔ Letara ✔ Promethazine Winthrop Elixir

144 146 151 155

120 dose OP ✔ Flixonase Hayfever & Allergy

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 January 2010

26 52 59 MESALAZINE Tab EC 500 mg ...................................................................... 49.50 PINDOLOL ❋ Tab 5 mg ................................................................................. 5.40 ❋ Tab 10 mg ............................................................................... 9.19 ❋ Tab 15 mg ............................................................................. 13.80 SILVER SULPHADIAZINE Crm 1% .................................................................................. 12.30 a) Up to 250 g available on a PSO b) Not in combination 100 100 100 100 50 g OP ✔ Asamax ✔ Apo-Pindolol ✔ Apo-Pindolol ✔ Apo-Pindolol ✔ Flamazine

SOLIFENACIN SUCCINATE – Special Authority see SA0998 – Retail pharmacy Tab 5 mg ................................................................................ 56.50 30 ✔ Vesicare Tab 10 mg .............................................................................. 56.50 30 ✔ Vesicare ➽ SA0998 Special Authority for Subsidy Initial application from any relevant practitioner. Applications valid without further renewal unless notified for applications where the patient has overactive bladder and a documented intolerance of oxybutynin. FLUCLOXACILLIN SODIUM Cap 250 mg – Up to 30 cap available on a PSO ....................... 32.00 Cap 500 mg ......................................................................... 110.00 PARACETAMOL WITH CODEINE ❋ Tab paracetamol 500 mg with codeine phosphate 8 mg ............. 2.45 250 500 100 ✔ AFT ✔ AFT ✔ ParaCode

112

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 April 2010

67 IMIQUIMOD – Special Authority see SA0923 below – Retail pharmacy Crm 5% sachet ..................................................................... 110.40 12 ✔ Aldara ➽ SA0923 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following: 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate. Notes: Superficial basal cell carcinoma • Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance. • Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears. • Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma. External anogenital warts • Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata). Renewal from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following: 1 Inadequate response to initial treatment for anogenital warts; or 2 New confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or 3 Inadequate response to initial treatment for superficial basal cell carcinoma. Note: Every effort should be made to biopsy Confirmation that the lesion to confirm that it is a superficial basal cell carcinoma should be obtained using a biopsy. SOMATROPIN – Special Authority see SA0755 ❋ Inj cartridge 16 iu per vial (5.3 mg) ........................................ 160.00 ❋ Inj cartridge 36 iu per vial (12 mg) ......................................... 360.00 NYSTATIN Tab 500,000 u ......................................................................... 9.60 1 1 ✔ Genotropin ✔ Genotropin

79 87

✔ Nilstat S29

INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available between 1 March and 30 June each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2010 (continued)

continued... iii)diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin. c) people under 65 years of age who are: i) pregnant; or ii) morbidly obese d) children under the age of 5 who are enrolled with an Access Primary Health Organisation aged over 6 months and under 5 years who are from high deprivation backgrounds The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease. B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj ............................................................................................ 9.00 1 ✔ Fluvax 90.00 10 ✔ Influvac ✔ Vaxigrip

106

ALENDRONATE FOR OSTEOPOROSIS ALENDRONATE SODIUM – Special Authority see SA0990 – Retail pharmacy Tab 70 mg ............................................................................. 35.91

✔ Fosamax

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA0990 – Retail pharmacy Tab 70 mg with cholecalciferol 2800 iu ................................... 35.91 4 ✔ Fosamax Plus Tab 70 mg with cholecalciferol 5600 iu ................................... 35.91 4 ✔ Fosamax Plus ➽ SA0990 Special Authority for Subsidy Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2010 (continued)

continued... 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo) which incorporates BMD measurements (see Note). Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and 2 Either: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically. Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents). Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the Underlying cause osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo) which incorporates BMD measurements (see Note). Notes: a) T-Score must be derived using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. a)b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates. b)c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. c)d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2010 (continued)

116 GABAPENTIN – Special Authority see SA1009 0936 – Retail pharmacy s Cap 100 mg ............................................................................. 7.16 100 ✔ Nupentin s Cap 300 mg ........................................................................... 11.50 100 ✔ Nupentin s Cap 400 mg ........................................................................... 14.75 100 ✔ Nupentin ➽ SA1009 0936 Special Authority for Subsidy Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Either: 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application - (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin, topiramate, vigabatrin and /or lamotrigine. for applications meeting the following criteria: Either: 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin; or 2 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents, or seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective. Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant. Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site. Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or continued... ❋ Three months or six months, as applicable, dispensed all-at-once

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2010 (continued)

continued... 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site. Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 118 VIGABATRIN – Special Authority see SA1010 0937– Retail pharmacy s Tab 500 mg ......................................................................... 119.30 100 ✔ Sabril ➽ SA1010 0937 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient has infantile spasms; or 1.2 Both: 1.2.1 Patient has epilepsy; and 1.2.2 Either: 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and 2 Either: 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life from gabapentin, topiramate, vigabatrin and or lamotrigine; and 2 Either: 1 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or 2 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2010 (continued)

continued... 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

159

TRAVOPROST – Retail pharmacy-Specialist See prescribing guideline Additional subsidy by endorsement is available for patients who were being prescribed travoprost prior to 1 April 2010. Note additional subsidy valid until 30 September 2010. Pharmacists may annotate prescriptions for patients who were being prescribed travoprost prior to 1 April 2010 in which case the prescription is deemed to be endorsed. The pharmacist must be able to show a clear documented dispensing history for the patient. The prescription must be endorsed accordingly. 2.5 ml OP s Eye drops 0.004% .................................................................... 9.75 (19.50) Travatan

Effective 1 March 2010

33 URSODEOXYCHOLIC ACID – Special Authority see SA1003 0914 – Retail pharmacy Cap 300 mg .......................................................................... 179.00 100 ✔ Actigall ➽ SA1003 0914 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Either 1. Patient diagnosed with cholestasis of pregnancy; or 2. Both: 1 2.1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 2.2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Note: Ursodeoxycholic acid Actigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation. 53 DILTIAZEM HYDROCHLORIDE ❋ Cap long-acting 120 mg (once per day) ..................................... 4.34 30 ✔ Cardizem CD

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2010 (continued)

55 NICOTINE a) Maximum of 768 piece per prescription b) Maximum of 384 piece per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 384 piece per dispensing cannot be waived via Access Exemption Criteria. Gum 2 mg (Fruit) ..................................................................... 14.97 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 2 mg (Mint)..................................................................... 14.97 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 4 mg (Fruit) ..................................................................... 20.02 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 4 mg (Mint)..................................................................... 20.02 96 OP ✔ Habitrol 23.41 ✔ Nicotinell NICOTINE a) Maximum of 432 loz per prescription b) Maximum of 216 loz per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 216 loz per dispensing cannot be waived via Access Exemption Criteria. Lozenge 1 mg ......................................................................... 11.08 36 OP ✔ Habitrol Lozenge 2 mg ......................................................................... 11.08 36 OP ✔ Habitrol NICOTINE a) Maximum of 56 patch per prescription b) Maximum of 28 patch per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 28 patch per dispensing cannot be waived via Access Exemption Criteria. Patch 7 mg ............................................................................ 10.53 7 OP ✔ Habitrol Patch 14 mg ........................................................................... 11.63 7 OP ✔ Habitrol Patch 21 mg ........................................................................... 12.32 7 OP ✔ Habitrol INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available between 1 March and 30 June each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii)diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2010 (continued)

continued... d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin. c) people under 65 years of age who are: i) pregnant; or ii) morbidly obese d) children under the age of 5 who are enrolled with an Access Primary Health Organisation The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease. c) pregnancy in the absence of another risk factor. B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj ............................................................................................. 9.00 1 ✔ Fluvax ✔ Fluarix 90.00 10 ✔ Fluarix ✔ Influvac ✔ Vaxigrip

125

TRIFLUOPERAZINE HYDROCHLORIDE Tab 1 mg .................................................................................. 9.83 Tab 2 mg ................................................................................ 14.64 Tab 5 mg ................................................................................ 16.66

100 100 100

✔ Stelazine S29 ✔ Stelazine S29 ✔ Stelazine S29

Effective 1 February 2010

73 PREGNANCY TESTS - HCG URINE – Only on a PSO WSO Cassette – Up to 200 test available on a PSO ......................... 19.00 25 test OP ✔ MDS Quick Card Distributed by MDS Diagnostics, PO Box 24-162, Royal Oak, Auckland. Ph 09 570 5761 INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available between 1 March and 30 June each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; continued... Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 February 2010 (continued)

continued... iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin. c) people under 65 years of age who are: (i) pregnant; or (ii) morbidly obese d) children under the age of 5 who are enrolled with an Access Primary Health Organisation The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease, c) pregnancy in the absence of another risk factor. B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj ............................................................................................ 9.00 1 ✔ Fluvax ✔ Fluarix 90.00 10 ✔ Fluarix ✔ Vaxigrip

146

EXEMESTANE – Additional subsidy by Special Authority see SA1000 – Retail pharmacy Tab 25 mg ............................................................................. 26.55 30 (175.00) Aromasin ➽ SA1000 Special Authority for Alternate Subsidy Initial Application – from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1. Patient is a postmenopausal woman; and 2. Patient has hormone receptor positive breast cancer; and 3. Any of the following 3.1 The patient was receiving funded exemestane prior to 1 February 2010; or 3.2 The patient has advanced breast cancer and a very clear history of intolerance to anastrozole or letrozole; or 3.3 The patient has advanced breast cancer and disease has progressed following treatment with anastrozole or letrozole. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefitting from treatment. Note – Repeat dispensings for Aromasin tab 25 mg will be fully subsidised where the initial dispensing was before 1 February 2010.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2010

79 80 149 SOMATROPIN GROWTH HORMONE BIOSYNTHETIC HUMAN – Special Authority see SA0755 ❋ Inj cartridge 16 iu per vial ..................................................... 249.60 1 ✔ Genotropin 1,248.00 5 ✔ Genotropin ❋ Inj cartridge 36 iu per vial ..................................................... 561.60 1 ✔ Genotropin 2,808.00 5 ✔ Genotropin SOMATROPIN RECOMBINANT HUMAN GROWTH HORMONE – Special Authority see SA0755 ❋ Inj 5 mg ............................................................................... 300.00 1 ✔ Norditropin SimpleXx 5 mg ❋ Inj 10 mg ............................................................................. 600.00 1 ✔ Norditropin SimpleXx 10 mg ❋ Inj 15 mg ............................................................................. 900.00 1 ✔ Norditropin SimpleXx 15 mg CYCLOSPORIN A – Hospital pharmacy [HP3] Cap 25 mg ............................................................................. 59.50 50 Cap 50 mg ........................................................................... 118.54 50 Cap 100 mg ......................................................................... 237.08 50 Oral liq 100 mg per ml .......................................................... 264.17 50 ml OP Note – change in chemical name from cyclosporin A to cyclosporin only. ✔ Neoral ✔ Neoral ✔ Neoral ✔ Neoral

179

ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid (coffee latte) .................................................................. 1.33 237 ml OP ✔ Ensure Plus

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 April 2010

34 34 36 40 72 BISACODYL – Only on a prescription ( subsidy) ❋ Suppos 5 mg ............................................................................ 3.00 DOCUSATE SODIUM WITH SENNOSIDES ( subsidy) ❋ Tab 50 mg with total sennosides 8 mg ...................................... 6.38 HYDROXOCOBALAMIN ( subsidy) ❋ Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO ................ 6.15 (10.84) TRANEXAMIC ACID ( subsidy) Tab 500 mg ........................................................................... 32.92 6 200 3 Neo-B12 100 ✔ Cyklokapron ✔ Dulcolax ✔ Laxsol

ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID ( price) Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator ............................................................................. 8.43 100 g OP (24.00) SOMATROPIN – Special Authority see SA0755 ( subsidy) ❋ Inj cartridge 16 iu (5.3 mg) .................................................... 160.00 ❋ Inj cartridge 36 iu (12 mg) ..................................................... 360.00 1 1

Aci-Jel ✔ Genotropin ✔ Genotropin

79 93

ZIDOVUDINE [AZT] – Special Authority see SA0779 – Hospital pharmacy [HP1] ( subsidy) Cap 100 mg ......................................................................... 145.00 100 ✔ Retrovir Oral liq 10 mg per ml .............................................................. 29.00 200 ml OP ✔ Retrovir DIHYDROCODEINE TARTRATE ( subsidy) Tab long-acting 60 mg ........................................................... 27.27 MITOMYCIN C – PCT only – Specialist ( subsidy) Inj 10 mg .............................................................................. 808.00 Inj 1 mg for ECP ...................................................................... 16.13 LETROZOLE ( subsidy) Tab 2.5 mg ............................................................................ 26.55 (146.46) PROMETHAZINE HYDROCHLORIDE ( subsidy) ❋‡ Oral liq 5 mg per 5 ml ............................................................. 3.10 (8.51) CHLORAMPHENICOL ( subsidy) Eye drops 0.5% ........................................................................ 2.40 PREDNISOLONE ACETATE ( price) ❋ Eye drops 0.12% ...................................................................... 4.50 ❋ Eye drops 1% ........................................................................... 4.50 60 5 1 mg 30 Femara 100 ml Phenergan 10 ml OP 5 ml OP 5 ml OP ✔ Chlorsig ✔ Pred Mild ✔ Pred Forte ✔ DHC Continus ✔ Mitomycin-C S29 ✔ Baxter

111 142

146

151 157 158

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 April 2010 (continued)

159 TRAVOPROST – Retail pharmacy-Specialist ( subsidy) See prescribing guideline Additional subsidy by endorsement is available for patients who were being prescribed travoprost prior to 1 April 2010. Note additional subsidy valid until 30 September 2010. Pharmacists may annotate prescriptions for patients who were being prescribed travoprost prior to 1 April 2010 in which case the prescription is deemed to be endorsed. The pharmacist must be able to show a clear documented dispensing history for the patient. The prescription must be endorsed accordingly. s Eye drops 0.004% .................................................................... 9.75 2.5 ml OP (19.50) Travatan

Effective 1 March 2010

26 112 SULPHASALAZINE ( subsidy) ❋ Tab 500 mg ........................................................................... 11.68 ❋ Tab EC 500 mg ...................................................................... 12.89 PARACETAMOL WITH CODEINE ( subsidy) ❋ Tab paracetamol 500 mg with codeine phosphate 8 mg ................................................................... 2.45 (3.24) APOMORPHINE HYDROCHLORIDE ( subsidy) s Inj 10 mg per ml, 2 ml .......................................................... 110.00 LITHIUM CARBONATE ( subsidy) Tab long-acting 400 mg ......................................................... 17.65 LORAZEPAM – Month Restriction ( subsidy) Tab 1 mg ............................................................................... 16.42 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 2.5 mg ............................................................................ 11.17 ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 100 ✔ Salazopyrin ✔ Salazopyrin EN

100 Codalgin 5 100 250 100 ✔ Apomine ✔ Priadel ✔ Ativan ✔ Ativan

121 124 127

Effective 9 February 2010

140 DOCETAXEL – PCT only – Specialist – Special Authority see SA0880 ( subsidy) Inj 1 mg for ECP ..................................................................... 23.81 1 mg ✔ Baxter

Effective 1 February 2010

36 CALCITRIOL ( subsidy) ❋ Cap 0.25 µg ........................................................................... 10.10 ❋ Cap 0.5 µg ............................................................................. 18.73 36 HYDROXOCOBALAMIN ( subsidy) ❋ Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO ................ 6.15 100 100 3 ✔ Calcitriol-AFT ✔ Calcitriol-AFT ✔ ABM Hydroxocobalamin

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 February 2010 (continued)

50 FLECAINIDE ACETATE – Retail pharmacy–Specialist ( subsidy) s Tab 50 mg .............................................................................. 45.82 s Tab 100 mg ............................................................................ 80.92 s Cap long-acting 100 mg .......................................................... 45.82 s Cap long-acting 200 mg .......................................................... 80.92 Inj 10 mg per ml, 15 ml ........................................................... 52.45 METOPROLOL SUCCINATE ( subsidy) ❋ Tab long-acting 23.75 mg ......................................................... 2.73 ❋ Tab long-acting 47.5 mg ........................................................... 3.41 ❋ Tab long-acting 95 mg .............................................................. 5.88 ❋ Tab long-acting 190 mg .......................................................... 10.63 60 60 30 30 5 30 30 30 30 ✔ Tambocor ✔ Tambocor ✔ Tambocor CR ✔ Tambocor CR ✔ Tambocor ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR ✔ Viagra ✔ Viagra

SILDENAFIL – Special Authority see SA0968 – Hospital pharmacy [HP1] ( subsidy) Tab 25 mg .............................................................................. 52.00 4 Tab 100 mg ............................................................................ 68.00 4 PERMETHRIN ( subsidy) Crm 5% .................................................................................... 3.65 (4.20) CALCIPOTRIOL ( subsidy) Crm 50 µg per g...................................................................... 20.20 56.32 Oint 50 µg per g ...................................................................... 20.20 56.32 Soln 50 µg per ml ................................................................... 20.22 33.79 GOSERELIN ACETATE – Hospital pharmacy [HP3] ( subsidy) Inj 3.6 mg ............................................................................. 200.00 Inj 10.8 mg ........................................................................... 500.00 SUMATRIPTAN ( subsidy) Tab 50 mg ................................................................................ 1.55 (12.00) (22.00) Tab 100 mg .............................................................................. 1.55 (12.00) (22.00) PIZOTIFEN ( price) ❋ Tab 500 µg ............................................................................ 21.10 30 g OP

Lyderm 30 g OP 100 g OP 30 g OP 100 g OP 30 ml OP 60 ml OP 1 1 4 2 ✔ Daivonex ✔ Daivonex ✔ Daivonex ✔ Daivonex ✔ Daivonex ✔ Daivonex ✔ Zoladex ✔ Zoladex ✔ Arrow-Sumatriptan Sumagran Imigran ✔ Arrow-Sumatriptan Sumagran Imigran ✔ Sandomigran ✔ Baxter ✔ Arimidex

119

120 140 145

100

DOCETAXEL – PCT only – Specialist – Special Authority see SA0880 ( subsidy) Inj 1 mg for ECP ..................................................................... 17.55 1 mg ANASTROZOLE ( subsidy) Tab 1 mg ............................................................................... 26.55 30

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 February 2010 (continued)

146 EXEMESTANE – Additional subsidy by Special Authority see SA1000 – Retail pharmacy ( subsidy) Tab 25 mg .............................................................................. 26.55 30 (175.00) Aromasin

Effective 1 January 2010

30 METFORMIN HYDROCHLORIDE ( subsidy) ❋ Tab immediate-release 500 mg.................................................. 8.09 ❋ Tab immediate-release 850 mg.................................................. 6.67 GLYCEROL ( subsidy) ❋ Suppos 3.6 g – Only on a prescription ....................................... 6.00 CHOLECALCIFEROL ( subsidy) ❋ Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription........................................ 7.76 FOLIC ACID ( subsidy) ❋ Tab 0.8 mg ............................................................................ 19.80 ❋ Tab 5 mg ............................................................................... 10.21 HYDROCORTISONE BUTYRATE ( subsidy) Lipocream 0.1% ........................................................................ 2.30 6.85 Oint 0.1% .................................................................................. 6.85 Milky emul 0.1% ........................................................................ 6.85 500 250 20 ✔ Arrow-Metformin ✔ Arrow-Metformin ✔ PSM

34 37

12 1,000 500 30 g OP 100 g OP 100 g OP 100 ml OP

✔ Cal-d-Forte ✔ Apo-Folic Acid ✔ Apo-Folic Acid ✔ Locoid Lipocream ✔ Locoid Lipocream ✔ Locoid ✔ Locoid Crelo

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription ( subsidy) Crm 1% with natamycin 1% and neomycin sulphate 0.5% .......... 2.79 15 g OP ✔ Pimafucort Oint 1% with natamycin 1% and neomycin sulphate 0.5% .......... 2.79 15 g OP ✔ Pimafucort MOMETASONE FUROATE ( subsidy) Crm 0.1% .................................................................................. 2.38 4.55 Oint 0.1% .................................................................................. 2.38 4.55 WOOL FAT WITH MINERAL OIL – Only on a prescription ( price) ❋ Lotn hydrous 3% with mineral oil ............................................... 1.40 (3.50) HYDROCORTISONE BUTYRATE ( subsidy) Scalp lotn 0.1% ......................................................................... 3.65 MEDROXYPROGESTERONE ACETATE ( subsidy) ❋ Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO ............................................. 7.15 CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL ( subsidy) ❋ Tab 2 mg with ethinyloestradiol 35 μg and 7 inert tabs ............... 4.91 (6.30) Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. 15 g OP 45 g OP 15 g OP 45 g OP 250 ml OP Hydroderm Lotion 100 ml OP ✔ Locoid ✔ Elocon ✔ Elocon ✔ Elocon ✔ Elocon

66 72

1 84

✔ Depo-Provera

Estelle 35-ED

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 January 2010 (continued)

77 MEDROXYPROGESTERONE ACETATE ❋ Tab 2.5 mg ( subsidy) ............................................................. 3.09 ❋ Tab 5 mg ( subsidy) .............................................................. 13.06 ❋ Tab 10 mg ( subsidy) .............................................................. 6.85 MEDROXYPROGESTERONE ACETATE ( subsidy) ❋ Tab 100 mg – Retail pharmacy – Specialist ............................. 96.50 ❋ Tab 200 mg – Retail pharmacy – Specialist ............................. 70.50 SOMATROPIN – Special Authority see SA0755 ( subsidy) ❋ Inj cartridge 16 iu per vial ...................................................... 249.60 1,248.00 ❋ Inj cartridge 36 iu per vial ...................................................... 561.60 2,808.00 CABERGOLINE ( subsidy) Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA0175 .................. 16.50 66.00 AMOXYCILLIN CLAVULANATE ( subsidy) Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml – Up to 200 ml available on a PSO ......................................... 2.20 (2.75) Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml – Up to 200 ml available on a PSO ......................................... 3.85 (4.75) CLINDAMYCIN ( subsidy) Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy – Specialist............................................................................. 16.00 ISONIAZID – Retail pharmacy – Specialist ( subsidy) No patient co-payment payable ❋ Tab 100 mg ............................................................................ 20.00 ETIDRONATE DISODIUM ( subsidy) ❋ Tab 200 mg ............................................................................ 14.37 (22.80) 23.95 QUININE SULPHATE ( price) ❋ Tab 200 mg ............................................................................ 15.95 (17.20) ‡ Safety cap for extemporaneously compounded oral liquid preparations. CODEINE PHOSPHATE ( subsidy) Tab 15 mg ................................................................................ 5.39 Tab 30 mg ................................................................................ 8.25 Tab 60 mg .............................................................................. 17.76 30 100 30 100 30 1 5 1 5 ✔ Provera ✔ Provera ✔ Provera ✔ Provera ✔ Provera ✔ Genotropin ✔ Genotropin ✔ Genotropin ✔ Genotropin

2 8

✔ Dostinex ✔ Dostinex

100 ml Augmentin 100 ml Augmentin

✔ Dalacin C

100 60 100 250

✔ PSM

108

Didronel ✔ Etidrate

109

Q 200

111

100 100 100

✔ PSM ✔ PSM ✔ PSM

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 January 2010 (continued)

113 PETHIDINE HYDROCHLORIDE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Tab 50 mg ................................................................................ 3.20 Tab 100 mg .............................................................................. 4.20 PHENOBARBITONE ( subsidy) ❋ Tab 15 mg .............................................................................. 25.00 ❋ Tab 30 mg .............................................................................. 26.00 ALPRAZOLAM – Month Restriction ( subsidy) Tab 250 µg .............................................................................. 3.15 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 µg .............................................................................. 4.10 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg .................................................................................. 7.25 ‡ Safety cap for extemporaneously compounded oral liquid preparations.

10 10 500 500 50 50 50

✔ PSM ✔ PSM ✔ PSM ✔ PSM ✔ Arrow-Alprazolam ✔ Arrow-Alprazolam ✔ Arrow-Alprazolam

118

127

131

DEXAMPHETAMINE SULPHATE – Special Authority see SA0907 – Retail pharmacy ( subsidy) Only on a controlled drug form Tab 5 mg ................................................................................ 16.50 100 ✔ PSM OXALIPLATIN – PCT only – Specialist – Special Authority see SA0900 ( subsidy) Inj 1 mg for ECP ........................................................................ 1.42 1 mg CYCLOSPORIN – Hospital pharmacy [HP3] ( subsidy) Cap 25 mg .............................................................................. 59.50 Cap 50 mg ............................................................................ 118.54 Cap 100 mg .......................................................................... 237.08 Oral liq 100 mg per ml ........................................................... 264.17 50 50 50 50 ml OP ✔ Baxter ✔ Neoral ✔ Neoral ✔ Neoral ✔ Neoral

136 149

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 March 2010

14 “Cost, Brand, Source of Supply” means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor’s annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

Changes to Sole Subsidised Supply

Effective 1 April 2010

For the list of new Sole Subsidised Supply products effective 1 April 2010 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 11-19.

Changes to Section E Part I

Effective 1 February 2010

Pharmaceuticals and quantities that may be obtained on a Practitioner’s Supply Order 189 PREGNANCY TESTS – HCG URINE ✔ Cassette 200 test Pharmaceuticals that may be obtained on a Wholesale Supply Order 190 PREGNANCY TESTS - HCG URINE ✔ Cassette

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 April 2010

40 42 62 PHYTOMENADIONE Tab 10 mg ................................................................................ 5.60 HEPARINISED SALINE ❋ Inj 10 iu per ml, 5 ml ............................................................... 18.00 MOMETASONE FUROATE Crm 0.1% .................................................................................. 2.38 4.55 Oint 0.1% .................................................................................. 2.38 4.55 CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL ❋ Tab 2 mg with ethinyloestradiol 35 μg and 7 inert tabs ............... 4.91 (6.30) 10 50 15 g OP 45 g OP 15 g OP 45 g OP 84 Estelle 35-ED ✔ Genotropin ✔ Genotropin ✔ Konakion ✔ AstraZeneca ✔ Elocon ✔ Elocon ✔ Elocon ✔ Elocon

79 84

SOMATROPIN – Special Authority see SA0755 ❋ Inj cartridge 16 iu (5.3 mg) ................................................. 1,248.00 5 ❋ Inj cartridge 36 iu (12 mg) .................................................. 2,808.00 5 Note – Genotropin inj cartridge 16 iu and 36 iu 1 injection packs remain subsidised. AMOXYCILLIN CLAVULANATE Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml – Up to 200 ml available on a PSO ......................................... 2.20 (2.75) Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml – Up to 200 ml available on a PSO ......................................... 3.85 (4.75) INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj ............................................................................................ 9.00 90.00 ETIDRONATE DISODIUM ❋ Tab 200 mg ............................................................................ 14.37 (22.80) 23.95 DIAZEPAM Tab 10 mg – Month Restriction.................................................. 3.45 ‡ Safety cap for extemporaneously compounded oral liquid preparations. PILOCARPINE ❋ Eye drops 4% ............................................................................ 6.57

100 ml Augmentin 100 ml Augmentin 1 10 60 100 100 Didronel ✔ Etidrate ✔ Pro-Pam ✔ Fluarix ✔ Fluarix

108

127

160 176

15 ml OP

✔ Pilopt

SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA0592 – Hospital pharmacy [HP3] Liquid ....................................................................................... 6.02 500 ml OP ✔ Peptisorb

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 March 2010

97 PEGYLATED INTERFERON ALPHA-2B WITH RIBAVIRIN – Special Authority see SA0953 – Hospital pharmacy [HP3] See prescribing guideline Inj 50 μg × 4 with ribavirin cap 200 mg × 112 ................. 1,080.40 1 OP ✔ Pegatron Combination Therapy Inj 50 μg × 4 with ribavirin cap 200 mg × 84 ...................... 976.80 1 OP ✔ Pegatron Combination Therapy Inj 80 μg × 4 with ribavirin cap 200 mg × 140 ................. 1,583.60 1 OP ✔ Pegatron Combination Therapy Inj 80 μg × 4 with ribavirin cap 200 mg × 168 ................. 1,687.20 1 OP ✔ Pegatron Combination Therapy Inj 80 μg × 4 with ribavirin cap 200 mg × 84 ................... 1,376.40 1 OP ✔ Pegatron Combination Therapy Inj 100 μg × 4 with ribavirin cap 200 mg × 112 ............... 1,746.40 1 OP ✔ Pegatron Combination Therapy Inj 100 μg × 4 with ribavirin cap 200 mg × 84 ................. 1,642.80 1 OP ✔ Pegatron Combination Therapy Inj 120 μg × 4 with ribavirin cap 200 mg × 140 ............... 2,116.40 1 OP ✔ Pegatron Combination Therapy Inj 120 μg × 4 with ribavirin cap 200 mg × 84 ................. 1,909.20 1 OP ✔ Pegatron Combination Therapy Inj 150 μg × 4 with ribavirin cap 200 mg × 140 ............... 2,516.00 1 OP ✔ Pegatron Combination Therapy Inj 150 μg × 4 with ribavirin cap 200 mg × 168 ............... 2,619.60 1 OP ✔ Pegatron Combination Therapy Inj 150 μg × 4 with ribavirin cap 200 mg × 84 ................. 2,308.80 1 OP ✔ Pegatron Combination Therapy DICLOFENAC SODIUM ❋ Tab EC 25 mg .......................................................................... 3.26 (3.51) ❋ Tab EC 50 mg ........................................................................ 21.30 (25.88) TRIMIPRAMINE MALEATE Cap 25 mg ............................................................................... 6.20 LAMOTRIGINE s Tab dispersible 200 mg ........................................................ 101.80 100 Apo-Diclo 500 Apo-Diclo 100 56 ✔ Tripress ✔ Mogine

101 115 117

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 March 2010 (continued)

121 127 BROMOCRIPTINE MESYLATE ❋ Tab 10 mg ........................................................................... 120.86 DIAZEPAM Tab 5 mg – Month Restriction.................................................... 5.00 ‡ Safety cap for extemporaneously compounded oral liquid preparations. PACLITAXEL – PCT only – Specialist Inj 30 mg ................................................................................ 37.95 Note – Paclitaxel Ebewe inj 30 mg, 5 inj pack remains listed. LATANOPROST – Retail pharmacy-Specialist See prescribing guideline s Eye drops 50 µg per ml, 2.5ml ................................................. 9.75 (19.50) PILOCARPINE ❋ Eye drops 1% ........................................................................... 3.24 100 250 ✔ Alpha-Bromocriptine ✔ Pro-Pam

142

✔ Paclitaxel Ebewe

159 160 181

2.5 ml OP Xalatan 15 ml OP ✔ Pilopt

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Corn and Spinach Rigatini ......................................................... 2.00 250 g OP (2.92) Garlic and Parsley Shells .......................................................... 2.00 250 g OP (2.92) Rice and Corn Garden Herb Pasta ............................................. 2.00 250 g OP (2.92)

Orgran Orgran Orgran

Effective 1 February 2010

30 51 54 58 GLIBENCLAMIDE ❋ Tab 2.5 mg .............................................................................. 3.78 ❋ Tab 5 mg ................................................................................. 3.31 ACEBUTOLOL ❋ Cap 100 mg ............................................................................. 9.50 TRIAMTERENE WITH HYDROCHLOROTHIAZIDE ❋ Tab 50 mg with hydrochlorothiazide 25 mg ............................... 5.00 ISOTRETINOIN – Special Authority see SA0955 – Retail pharmacy Cap 10 mg ............................................................................. 26.93 Cap 20 mg ............................................................................. 38.72 SAQUINAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Tab 500 mg ......................................................................... 556.59 DIAZEPAM Tab 2 mg – Month Restriction.................................................... 8.40 ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 100 100 100 100 100 120 500 ✔ Gliben ✔ Gliben ✔ ACB ✔ Triamizide ✔ Isotane 10 ✔ Isotane 20 ✔ Invirase ✔ Pro-Pam

93 127

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 February 2010 (continued)

150 151 AZATADINE MALEATE ❋ Tab 1 mg ................................................................................. 6.94 (16.90) BECLOMETHASONE DIPROPIONATE Aerosol inhaler, 50 µg per dose ................................................ 8.54 Aerosol inhaler, 100 µg per dose ............................................ 12.50 Aerosol inhaler, 250 µg per dose ............................................ 22.67 Note – Beclazone CFC-free aerosol inhalers were listed 1 July 2009 PILOCARPINE ❋ Eye drops 6% ........................................................................... 8.56 50 Zadine 200 dose OP ✔ Beclazone 50 200 dose OP ✔ Beclazone 100 200 dose OP ✔ Beclazone 250

160

15 ml OP

✔ Pilopt

Effective 1 January 2010

60 CALAMINE a) Only on a prescription b) Not in combination Crm, aqueous, BP ..................................................................... 2.78 (3.02) Lotn, BP .................................................................................. 16.70 (19.44) MEDROXYPROGESTERONE ACETATE ❋ Inj 150 mg per ml, 1 ml – Up to 5 inj available on a PSO ............ 8.05 CO-TRIMOXAZOLE ❋ Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO............... 5.90 DEXTROCHLORPHENIRAMINE MALEATE ❋ Tab long-acting 6 mg ................................................................ 2.70 (7.73) 5.40 (12.56) PILOCARPINE ❋ Eye drops 2% ............................................................................ 4.32

100 g ABM 2,000 ml ABM 1 ✔ Depo-Provera

72 86

500 ml 20

✔ Trisul

151

Polaramine Repetab 40 Polaramine Repetab 15 ml OP

160

✔ Pilopt

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 May 2010

30 METFORMIN HYDROCHLORIDE ❋ Tab immediate-release 500 mg.................................................. 8.09 ❋ Tab immediate-release 850 mg.................................................. 6.67 CALCITRIOL ❋ Cap 0.25 µg ........................................................................... 10.10 ❋ Cap 0.5 µg ............................................................................. 18.73 64 PERMETHRIN Crm 5% .................................................................................... 3.65 (4.20) AMOXYCILLIN Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO ................................................................. 1.27 SUMATRIPTAN Tab 50 mg ................................................................................ 1.55 (12.00) (22.00) Tab 100 mg .............................................................................. 1.55 (12.00) (22.00) 500 250 100 100 30 g OP Lyderm ✔ Arrow-Metformin ✔ Arrow-Metformin ✔ Calcitriol-AFT ✔ Calcitriol-AFT

100 ml 4 2

✔ Ranbaxy Amoxicillin ✔ Arrow-Sumatriptan Sumagran Imigran ✔ Arrow-Sumatriptan Sumagran Imigran

119

Effective 1 June 2010

52 85 PINDOLOL ❋ Tab 5 mg ................................................................................. 4.50 ❋ Tab 10 mg ................................................................................ 8.35 ❋ Tab 15 mg ............................................................................. 12.00 FLUCLOXACILLIN SODIUM Cap 250 mg – Up to 30 cap available on a PSO ....................... 18.50 Cap 500 mg ............................................................................ 57.90 DICLOFENAC SODIUM ❋ Tab long-acting 75 mg ........................................................... 19.60 100 100 100 250 500 100 ✔ Pindol ✔ Pindol ✔ Pindol ✔ Staphlex ✔ Staphlex ✔ Voltaren SR

100 112 142

PARACETAMOL WITH CODEINE ❋ Tab paracetamol 500 mg with codeine phosphate 8 mg ............. 2.45 100 (3.24) Codalgin MITOMYCIN C – PCT only – Specialist Inj 10 mg .............................................................................. 808.00 5 ✔ Mitomycin-C S29 Note – The decision to delist Mitomycin C inj 10 mg has been revoked. It will remain listed.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 July 2010

36 59 HYDROXOCOBALAMIN ❋ Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO ................ 6.15 (10.84) SILVER SULPHADIAZINE Crm 1% with chlorhexidine digluconate 0.2% ........................... 15.04 a) Up to 500 g available on a PSO b) Not in combination HYDROCORTISONE BUTYRATE Milky emul 0.1% ........................................................................ 5.00 DITHRANOL Crm 1% ................................................................................... 27.50 SOMATROPIN – Special Authority see SA0755 ❋ Inj 5 mg ................................................................................ 300.00 ❋ Inj 10 mg .............................................................................. 600.00 ❋ Inj 15 mg .............................................................................. 900.00 138 146 FLUDARABINE PHOSPHATE – PCT only – Specialist Tab 10 mg ........................................................................... 650.25 LETROZOLE Tab 2.5 mg ............................................................................ 26.55 (146.46) PROMETHAZINE HYDROCHLORIDE ❋‡ Oral liq 5 mg per 5 ml ............................................................. 3.10 (8.51) 3 Neo-B12 100 g OP ✔ Silvazine

62 65 80

30 ml OP 50 g OP 1 1 1

✔ Locoid Crelo ✔ Micanol ✔ Norditropin SimpleXx 5 mg ✔ Norditropin SimpleXx 10 mg ✔ Norditropin SimpleXx 15 mg ✔ Fludara

15 30

Femara 100 ml Phenergan

151

Effective 1 August 2010

34 38 95 BISACODYL – Only on a prescription ❋ Suppos 10 mg .......................................................................... 3.96 FERROUS GLUCONATE WITH ASCORBIC ACID ❋ Tab 170 mg with ascorbic acid 40 mg ..................................... 12.04 12 500 ✔ Fleet ✔ Healtheries Iron with Vitamin C

INTERFERON ALPHA-2A – PCT – Hospital pharmacy [HP3]-Specialist a) See prescribing guideline b) Only one multidose cartridge starter pack to be prescribed and dispensed per patient. Inj 4.5 m iu prefilled syringe .................................................... 46.98 1 ✔ Roferon-A Inj 18 m iu multidose cartridge .............................................. 187.92 1 ✔ Roferon-A Inj 18 m iu multidose cartridge × 2 starter pack ................... 375.84 1 ✔ Roferon-A

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 August 2010 (continued)

95 INTERFERON ALPHA-2A WITH RIBAVIRIN – Special Authority see SA0784 – Hospital pharmacy [HP3] See prescribing guideline Inj 18 m iu multidose cartridge × 2 with ribavirin tab 200 mg × 168 .............................. 1,375.84 1 OP ✔ Roferon RBV Combination Pack Inj 18 m iu multidose cartridge × 2 with pen and needles with ribavirin tab 200 mg × 168 ............................................ 1,375.84 1 OP ✔ Roferon RBV Combination Pack Starter Kit TRIMIPRAMINE MALEATE Cap 50 mg .............................................................................. 11.20 DEXTROCHLORPHENIRAMINE MALEATE ❋ Tab long-acting 6 mg ................................................................ 5.40 (12.56) 2.70 (7.73) 100 40 Polaramine ColourFree Repetab 20 Polaramine ColourFree Repetab ✔ Tripress

114 151

Effective 1 September 2010

30 31 COPPER ❋ Tab, diagnostic – Not on a BSO ................................................. 5.02 (31.80) GLUCOSE OXIDASE Urine diagnostic test – Not on a BSO ......................................... 4.11 (7.00) Urine diagnostic test with peroxidase – Not on a BSO ................. 4.11 (6.26) 4.13 (8.65) MULTIVITAMINS – Special Authority see SA0963 – Retail pharmacy Tab ......................................................................................... 19.65 Oral liq .................................................................................... 13.50 AMOXYCILLIN Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO. ........................................ 1.00 36 OP Clinitest 50 strip OP Diabur 5000 50 strip OP Diastix Clinistix 100 ✔ Ketovite 150 ml OP ✔ Ketovite Liquid

100 ml

✔ Ranbaxy Amoxicillin

107 150 161

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA0990 – Retail pharmacy Tab 70 mg with cholecalciferol 2,800 iu................................... 35.91 4 ✔ Fosamax Plus CYPROHEPTADINE HYDROCHLORIDE ❋ Tab 4 mg .................................................................................. 6.27 PHENYLEPHRINE HYDROCHLORIDE WITH ZINC SULPHATE ❋ Eye drops 0.12% with zinc sulphate 0.25% ................................ 4.51 100 15 ml OP

✔ Periactin ✔ Zincfrin

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 October 2010

28 OMEPRAZOLE For omeprazole suspension refer, page 166 ❋ Cap 20 mg ................................................................................ 2.85 Note – Dr Reddy's Omeprazole cap 20 mg, 30 capsule pack, remains listed. 51 ACEBUTOLOL ❋ Cap 200 mg ........................................................................... 15.94 100 ✔ ACB

✔ Dr Reddy’s Omeprazole

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 April 2010

AMBRISENTAN Tab 5 mg........................................Volibris Tab 10 mg......................................Volibris BISACODYL Suppos 5 mg..................................Dulcolax Suppos 10 mg................................Dulcolax CHLORAMPHENICOL ( price) Eye drops 0.5% .............................Chlorsig CIPROFLOXACIN ( price and addition of HSS) Inj 2 mg per ml, 100 ml ..................Aspen Ciprofloxacin 4,585.00 4,585.00 3.00 3.00 2.40 41.00 30 30 6 6 10 ml 10 1% Jun-10 Ciproxin DBL DP-Cipro Topistin Ufexil

DANAZOL Cap 200 mg ...................................Azol DIHYDROCODEINE TARTRATE Tab long-acting 60 mg....................DHC Continus DOCUSATE SODIUM Tab 50 mg......................................Laxofast 50 Tab 120 mg....................................Laxofast 120

97.83 27.27 3.95 5.49

100 60 100 100 1% 1% 1% Jun-10 Jun-10 Jun-10 (B) Coloxyl Coloxyl

DOCUSATE SODIUM WITH SENNOSIDES ( price and addition of HSS) Tab 50 mg with total sennosides 8 mg .......................Laxsol 6.38 200 HYDROCORTISONE Crm 1% ..........................................Pharmacy Health 3.75 100 g

Jun-10

Coloxyl with Senna

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN (Amended chemical name) Crm 1% with natamycin 1% and neomycin sulphate 0.5% ............Pimafucort 2.79 15 g Oint 1% with natamycin 1% and neomycin sulphate 0.5% ............Pimafucort 2.79 15 g OMEPRAZOLE Cap 10 mg .....................................Dr Reddy’s 2.00 28 1% May-09 Losec Omeprazole Omezol Cap 20 mg .....................................Dr Reddy’s 2.85 28 1% May-09 Losec Omeprazole Omezol Cap 40 mg .....................................Dr Reddy’s 3.35 28 1% May-09 Losec Omeprazole Omezol Note – Dr Reddy’s Omeprazole cap 10 mg, 20 mg and 40 mg, 28 cap packs, to be delisted 1 June 2010. Please note that the 30 capsule packs remain listed. Products with Hospital Supply Status (HSS) are in bold. (B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes Part II - effective 1 April 2010 (continued)

PIPERACILLIN SODIUM WITH TAZOBACTAM SODIUM Inj 4 g with tazobactam sodium 500 mg .........................Tazocin EF TOPIRAMATE Tab 25 mg......................................Arrow -Topiramate Tab 50 mg......................................Arrow -Topiramate Tab 100 mg....................................Arrow -Topiramate Tab 200 mg....................................Arrow -Topiramate TRANEXAMIC ACID ( price and addition of HSS) Tab 500 mg....................................Cyclokapron ZIDOVUDINE (AZT) Cap 100 mg ...................................Retrovir Oral liq 10 mg per ml ......................Retrovir

12.00

Jun-10

DBL Zobacin

11.07 18.81 31.99 55.19

60 60 60 60

32.92 145.00 29.00

100 100 200 ml

1% 1% 1%

Jun-10 Jun-10 Jun-10

(B) (B) (B)

Section H changes to Part IV

Effective 1 April 2010

CLOPIDOGREL Tab 75 mg Plavix Up to 4 weeks supply post stenting. Not to be funded for acute coronary syndrome or transient ischaemic attacks.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A ABM Hydroxocobalamin ..................................... 35 ACB ............................................................. 43, 48 Acebutolol.................................................... 43, 48 Acetic acid with hydroxyquinoline and ricinoleic acid.................................................. 34 Aci-Jel ............................................................... 34 Actigall .............................................................. 29 Aidovudine [AZT] ............................................... 34 Aldara ................................................................ 24 Alendronate for osteoporosis .............................. 25 Alendronate sodium ........................................... 25 Alendronate sodium with cholecalciferol ....... 25, 47 Alpha-Bromocriptine .......................................... 43 Alprazolam ......................................................... 39 Ambrisentan ................................................ 20, 49 Amoxycillin .................................................. 45, 47 Amoxycillin clavulanate ................................ 38, 41 Anastrozole ........................................................ 36 Apo-Diclo........................................................... 42 Apo-Folic Acid ................................................... 37 Apo-Megestrol ................................................... 21 Apomine ............................................................ 35 Apomorphine hydrochloride ............................... 35 Apo-Pindolol ...................................................... 23 Apo-Risperidone ................................................ 22 Arimidex ............................................................ 36 Aromasin ..................................................... 32, 37 Arrow-Alprazolam .............................................. 39 Arrow-Metformin.......................................... 37, 45 Arrow-Sumatriptan ................................. 22, 36, 45 Arrow-Topiramate ........................................ 20, 50 Asamax ............................................................. 23 Aspen Ciprofloxacin ........................................... 49 Ativan ................................................................ 35 Augmentin ................................................... 38, 41 Azatadine maleate .............................................. 44 Azol ............................................................. 20, 49 B Beclazone 50 ..................................................... 44 Beclazone 100 ................................................... 44 Beclazone 250 ................................................... 44 Beclomethasone dipropionate............................. 44 Betaloc CR ......................................................... 36 Bisacodyl ......................................... 20, 34, 46, 49 Blood glucose diagnostic test meter ................... 22 Blood glucose diagnostic test strip ..................... 22 Bromocriptine mesylate...................................... 43 C Cabergoline........................................................ 38 Calamine............................................................ 44 Calcipotriol......................................................... 36 Calcitriol ...................................................... 35, 45 Calcitriol-AFT ............................................... 35, 45 Cal-d-Forte......................................................... 37 Cardizem CD ...................................................... 29 Chloramphenicol .......................................... 34, 49 Chlorhexidine gluconate ..................................... 20 Chlorsig ....................................................... 34, 49 Cholecalciferol ................................................... 37 Ciprofloxacin ...................................................... 49 Clindamycin ....................................................... 38 Clinistix .............................................................. 47 Clinitest.............................................................. 47 Clopidogrel ........................................................ 50 Co-trimoxazole ................................................... 44 Codalgin ...................................................... 35, 45 Codeine phosphate ............................................ 38 Copper............................................................... 47 Crotamiton ......................................................... 20 Cyclosporin.................................................. 33, 39 Cyclosporin A .................................................... 33 Cyklokapron ................................................. 34, 50 Cyproheptadine hydrochloride ............................ 47 Cyproterone acetate with ethinyloestradiol .... 37, 41 D Daivonex ............................................................ 36 Dalacin C ........................................................... 38 Danazol........................................................ 20, 49 Dasatinib............................................................ 22 Depo-Provera ............................................... 37, 44 Dexamphetamine sulphate.................................. 39 Dextrochlorpheniramine maleate ................... 44, 47 DHC Continus .............................................. 34, 49 Diabur 5000 ....................................................... 47 Diastix ............................................................... 47 Diazepam..................................................... 41, 43 Diclofenac sodium ....................................... 42, 45 Didronel ....................................................... 38, 41 Dihydrocodeine tartrate ................................ 34, 49 Diltiazem hydrochloride ...................................... 29 Dithranol ............................................................ 46 Docetaxel ..................................................... 35, 36 Docusate sodium ......................................... 20, 49 Docusate sodium with sennosides ............... 34, 49 Dostinex ............................................................ 38 Dr Reddy’s Omeprazole................................ 48, 49 Dr Reddy’s Risperidone...................................... 22 Dulcolax................................................. 20, 34, 49 E Elocon ......................................................... 37, 41 Ensure Plus........................................................ 33 Estelle 35-ED ............................................... 37, 41 Etidrate ........................................................ 38, 41

Index

Pharmaceuticals and brands Etidronate disodium ..................................... 38, 41 Exemestane ................................................. 32, 37 F Femara ........................................................ 34, 46 Ferrous gluconate with ascorbic acid .................. 46 Flamazine........................................................... 23 Flecainide acetate............................................... 36 Fleet................................................................... 46 Flixonase Hayfever & Allergy .............................. 22 Fluarix .............................................. 25, 31, 32, 48 Flucloxacillin sodium .................................... 23, 45 Fludara............................................................... 46 Fludarabine phosphate ....................................... 46 Fluticasone propionate ....................................... 22 Fluvax .................................................... 25, 31, 32 Folic acid ........................................................... 37 Fosamax ............................................................ 25 Fosamax Plus .............................................. 25, 47 G Gabapentin ........................................................ 27 Genotropin ................................. 24, 33, 34, 38, 41 Gliben ................................................................ 43 Glibenclamide .................................................... 43 Glucose oxidase................................................. 47 Gluten free pasta ................................................ 43 Glycerol ............................................................. 37 Goserelin acetate ............................................... 36 Growth hormone biosynthetic human ................. 33 H Habitrol .............................................................. 30 Healtheries Iron with Vitamin C ........................... 46 Heparinised saline .............................................. 41 Hydrocortisone ............................................ 20, 49 Hydrocortisone butyrate ............................... 37, 46 Hydrocortisone with natamycin and neomycin ........................................... 37, 49 Hydroderm Lotion .............................................. 37 Hydroxocobalamin ................................. 34, 35, 46 I Imigran ........................................................ 36, 45 Imiquimod ......................................................... 24 Influenza vaccine........................ 21, 24, 30, 31, 41 Influvac .................................................. 21, 25, 31 Innovacon hCG One Step Pregnancy Test Device 20 Interferon alpha-2a ............................................. 46 Interferon alpha-2a with ribavirin......................... 47 Invirase .............................................................. 43 Isoniazid ............................................................ 38 Isotane 10.......................................................... 43 Isotane 20.......................................................... 43 Isotretinoin ......................................................... 43 Itch-Soothe ........................................................ 20 K Ketovite ............................................................. 47 Ketovite Liquid ................................................... 47 Konakion ........................................................... 41 L Lamotrigine........................................................ 42 Latanoprost........................................................ 43 Laxofast 50 .................................................. 20, 49 Laxofast 120 ................................................ 20, 49 Laxsol .......................................................... 34, 49 Letara ................................................................ 22 Letrozole ................................................ 22, 34, 46 Lithium carbonate .............................................. 35 Locoid ............................................................... 37 Locoid Crelo ................................................ 37, 46 Locoid Lipocream .............................................. 37 Lorazepam ......................................................... 35 Lyderm ........................................................ 36, 45 M MDS Quick Card ................................................ 31 Medroxyprogesterone acetate................. 37, 38, 44 Megestrol acetate............................................... 21 Mesalazine ......................................................... 23 Metformin hydrochloride .............................. 37, 45 Methylphenidate hydrochloride extended-release 22 Metoprolol succinate .......................................... 36 Micanol.............................................................. 46 Mitomycin C ................................................ 34, 45 Mitomycin-C ................................................ 34, 45 Mogine .............................................................. 42 Mometasone furoate .................................... 37, 41 Multivitamins ..................................................... 47 N Neo-B12 ...................................................... 34, 46 Neoral .......................................................... 33, 39 Nicotine ............................................................. 30 Nicotinell ............................................................ 30 Nilstat ................................................................ 24 Norditropin SimpleXx 5 mg ........................... 33, 46 Norditropin SimpleXx 10 mg ......................... 33, 46 Norditropin SimpleXx 15 mg ......................... 33, 46 Nupentin ............................................................ 27 Nystatin ............................................................. 24 O Omeprazole.................................................. 48, 49 On Call Advanced ............................................... 22 Oral feed 1.5kcal/ml ........................................... 33 Orgran ............................................................... 43 Oxaliplatin .......................................................... 39 P Paclitaxel ........................................................... 43 Paclitaxel Ebewe ................................................ 43

Index

Pharmaceuticals and brands Paracetamol with codeine ...................... 23, 35, 45 ParaCode ........................................................... 23 Pegatron Combination Therapy ........................... 42 Pegylated interferon alpha-2b with ribavirin ......... 42 Peptisorb ........................................................... 41 Periactin ............................................................ 47 Permethrin ................................................... 36, 45 Pethidine hydrochloride ...................................... 39 Phenergan ................................................... 34, 46 Phenobarbitone .................................................. 39 Phenylephrine hydrochloride with zinc sulphate ................................................... 47 Phytomenadione ................................................ 41 Pilocarpine ............................................. 41, 43, 44 Pilopt ..................................................... 41, 43, 44 Pimafucort ................................................... 37, 49 Pindol ................................................................ 45 Pindolol ....................................................... 23, 45 Piperacillin sodium with tazobactam sodium ....... 50 Pizotifen ............................................................. 36 Plavix ................................................................. 50 Polaramine Colour-Free Repetab ........................ 47 Polaramine Repetab ........................................... 44 Pred Forte .......................................................... 34 Pred Mild ........................................................... 34 Prednisolone acetate .......................................... 34 Pregnancy tests - HCG urine .................. 20, 31, 40 Priadel ............................................................... 35 Promethazine Winthrop Elixir .............................. 22 Pro-Pam ...................................................... 41, 43 Promethazine hydrochloride ................... 22, 34, 46 Provera .............................................................. 38 Q Q 200 ................................................................ 38 Quinine sulphate ................................................ 38 R Ranbaxy Amoxicillin ..................................... 45, 47 Recombinant human growth hormone ................ 33 Retrovir ........................................................ 34, 50 Risperidone........................................................ 22 Ritalin LA ........................................................... 22 Roferon-A .......................................................... 46 Roferon RBV Combination Pack ......................... 47 Roferon RBV Combination Pack Starter Kit ......... 47 S Sabril ................................................................. 28 Salazopyrin ........................................................ 35 Salazopyrin EN ................................................... 35 Sandomigran ..................................................... 36 Saquinavir .......................................................... 43 Semi-elemental enteral feed 1kcal/ml.................. 41 Sildenafil ............................................................ 36 Silvazine ............................................................ 46 Silver sulphadiazine ...................................... 23, 46 Solifenacin succinate ......................................... 23 Somatropin .......................... 24, 33, 34, 38, 41, 46 Sprycel .............................................................. 22 Staphlex ............................................................. 45 Stelazine ............................................................ 31 Sulphasalazine ................................................... 35 Sumagran .................................................... 36, 45 Sumatriptan ........................................... 22, 36, 45 T Tambocor .......................................................... 36 Tambocor CR .................................................... 36 Tazocin EF ......................................................... 50 Topiramate................................................... 20, 50 Tranexamic acid ........................................... 34, 50 Travatan....................................................... 29, 35 Travoprost ................................................... 29, 35 Triamizide .......................................................... 43 Triamterene with hydrochlorothiazide.................. 43 Trifluoperazine hydrochloride .............................. 31 Trimipramine maleate ................................... 42, 47 Tripress ....................................................... 42, 47 Trisul ................................................................. 44 U Ursodeoxycholic acid ......................................... 29 V Vaxigrip ................................................. 25, 31, 32 Vesicare............................................................. 23 Viagra ................................................................ 36 Vigabatrin .......................................................... 28 Vitabdeck ........................................................... 20 Vitamins ............................................................ 20 Volibris ........................................................ 20, 49 Voltaren SR ........................................................ 45 W Wool fat with mineral oil ..................................... 37 X Xalatan............................................................... 43 Z Zadine................................................................ 44 Zidovudine (AZT) .......................................... 34, 50 Zincfrin .............................................................. 47 Zoladex .............................................................. 36

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 April 2010

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 April 2010 Cumulative for January, February, March and April 2010 Section H for April 2010 Contents Summary of PHARMAC decisions effective 1 April 2010 …. 3 Diclofenac sodium SR 75…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.